GFH375, an oral inhibitor of KRAS G12D, was given to 74 heavily pretreated patients with advanced solid tumours, 43 of them pancreatic. The confirmed response rate in pancreatic cancer was 35.1%, with median overall survival of 9.9 months. Grade 3 or worse treatment-related adverse events occurred in 36.5% of patients, and one death from septic shock was treatment related.
Why it is interesting: KRAS G12D is the commonest RAS mutation in solid tumours, and carries a poor prognosis.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Health today
-
Cancer
Where is cancer incidence rising and falling, what screening and new tests find earlier, and what treatment has done to survival.
13 this week -
Obesity, diabetes and GLP-1
Are obesity and diabetes still rising, what behavioural change and public policy do, and what difference do GLP-1s and other similar drugs make.
10 this week -
Heart and stroke
Whether deaths from heart disease and stroke have stopped falling, what is found earlier, what treatment and prevention do now, and what the deaths say.
4 this week -
Mental health
Deaths by suicide, the life expectancy gap in severe mental illness, and the physical disease that follows it: what mental illness costs in lives.
7 this week -
Dementia
Whether dementia is becoming more or less common, what is now found, what treatment and prevention do, and what the deaths say.
4 this week -
Frailty and multimorbidity
Whether the years added after 85 are healthy ones, how frailty and multiple conditions are measured, and where the data run out.
1 this week
